Product Information
ESCITALOPRAM 5 MG TABLET is a generic product labeled by Cipla USA Inc., priced at $0.0416 per EA under NDC 69097084705. Its NADAC has been published 530 times since Aug 10, 2016.
FDA first approved this application on Sep 11, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Cipla USA Inc.NDC
69097084705
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ESCITALOPRAM OXALATEApproval Type
Generic (ANDA)
FDA Application
ANDA078604FDA Approved
9/11/2012
TE Code
AB
On Market Since
6/16/2016
Pharmacological Classes
Price Statistics
The NADAC for ESCITALOPRAM 5 MG TABLET has been published 530 times since Aug 10, 2016, and over the history we have for it it has declined 64.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0416 per EA |
|---|---|
| All-time high | $0.1336 (Oct 12, 2016) |
| All-time low | $0.0328 (Nov 20, 2024) |
| 52-week high | $0.0439 |
| 52-week low | $0.0412 |
| Median price | $0.0567 |
| Average price | $0.0608 |
| Largest weekly change | +34.3% (Dec 21, 2016) |
| Weeks tracked | 530 |
| Tracking since | Aug 10, 2016 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Escitalopram market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin Reuptake Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ESCITALOPRAM 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ESCITALOPRAM 5 MG TABLET, manufactured by Cipla USA Inc., is $0.0416 per EA (NDC 69097084705), effective Sep 30, 2026.
How has the price of ESCITALOPRAM 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for ESCITALOPRAM 5 MG TABLET has declined 64.7%. It has been tracked across 530 weekly CMS publications since Aug 10, 2016.
What are the highest and lowest recorded NADAC prices for ESCITALOPRAM 5 MG TABLET?
Since Aug 10, 2016, the NADAC for ESCITALOPRAM 5 MG TABLET has ranged from a low of $0.0328 (Nov 20, 2024) to a high of $0.1336 (Oct 12, 2016), with a median of $0.0567 per EA.
Are there cheaper alternatives to ESCITALOPRAM 5 MG TABLET?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ESCITALOPRAM 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ESCITALOPRAM 5 MG TABLET?
ESCITALOPRAM 5 MG TABLET (NDC 69097084705) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.